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Lyme diseasea b s t r a c t
Outer membrane vesicles (OMVs) are nanoparticles produced by Gram-negative bacteria that can be used
as vaccines. The application of OMVs as vaccine component can be expanded by expressing heterologous
antigens on OMVs, creating an OMV-based antigen presenting platform. This study aims to develop a pro-
duction process for such OMV-based vaccines and studies a production method based on meningococcal
OMVs that express heterologous antigens on their surface. As a proof of concept, the Borrelia burgdorferi
antigens OspA and OspC were expressed on Neisseria meningitidis OMVs to create a concept anti-Lyme
disease vaccine. Production of OMVs released in the culture supernatant was induced by high dissolved
oxygen concentrations and purification was based on scalable unit operations. A crude recovery of 90 mg
OMV protein could be obtained per liter culture. Expressing heterologous antigens on the OMVs did
result in minor reduction of bacterial growth, while OMV production remained constant. The antigen
expression did not alter the OMV characteristics. This study shows that production of well characterized
OMVs containing heterologous antigens is possible with high yields by combining high oxygen concen-
trations with an optimized purification process. It is concluded that heterologous OMVs show potential as
a vaccine platform.
 2019 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Vaccination is one of the most successful inventions as vaccines
have saved many lives by preventing infectious diseases. Despite
the successes, infectious diseases remain a major source of mortal-
ity worldwide. The development of new vaccines is continuously
required as new infectious diseases emerge and there is an increas-
ing demand for therapeutic vaccines. There is thus a need for new
vaccine production technologies that enable more rapid produc-
tion of vaccines. Vaccine platforms can provide enhanced safety,
productivity and simplicity in vaccine development by thorough
initial development of the platform. A vaccine platform for prophy-
lactic vaccines aims at eliciting high and lasting antibody responses
against specific antigens, while eliciting a standard supportive
innate immune response. The design of the vaccine platform or
antigen presenting platform should be such that protection against
different infectious diseases can be induced by displaying different
antigens. Bacterial outer membrane vesicles (OMVs) are suitablecandidates for vaccine platforms. OMVs are nanoparticles derived
from Gram-negative bacteria and are highly immunogenic while
non-infective and non-replicating [7]. However, not all Gram-
negative pathogens are suitable OMV vaccine producers because
of their high pathogenicity, low growth rate, complex media
requirements, lack of genetic accessibility, or low OMV productiv-
ity. Adding heterologous antigens to OMVs creates an OMV-based
antigen presenting platform. Bacteria have been engineered so that
they produce heterologous antigens in OMVs [14,20]. Alternatively,
the antigen can be produced separately and added to the OMV
[22,26,29]. Besides targeting infectious disease targets, OMV-
based vaccine platforms can be designed as therapeutic vaccines
[15,19,39].
Gram-negative bacteria produce spontaneously released OMVs
(sOMVs) that are secreted in the culture medium. However, the
amount of sOMVs produced per amount of biomass is generally
low and therefore other methods of OMV production have been
developed, like extraction of vesicles from the bacterial cells by
detergents (dOMVs) or by EDTA or other detergent-free methods
(eOMVs) [13]. Detergent extraction has been used in the produc-
tion of OMVs since the detergent extraction reduces the
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use vaccine composition. However, with the development of
genetically detoxified LPS variants there remains no necessity of
detergent extraction to reduce the LPS toxicity of OMVs [48].
OMVs from Neisseria meningitidis (Nm) are well studied, used to
control outbreaks of serogroup B meningococcal disease, and Nm
dOMVs are included in the 4CMenB/Bexsero vaccine [34]. Here
we test the expression of heterologous antigens on both Nm eOMV
and Nm sOMV. Outer surface protein A (OspA) and Outer surface
protein C (OspC) of Borrelia burgdorferi were chosen as model anti-
gens. B. burgdorferi causes Lyme disease and is the most common
tick-borne illness in the Northern hemisphere [2,38]. Recombinant
OspA has been shown safe and effective in randomize controlled
trials and has been the basis of novel vaccine concepts [5,35,46].
These model antigens are surface expressed because we hypothe-
size that surface exposure of antigens is advantageous. However,
the induction of antibody responses has also been shown for anti-
gens expressed in the OMV lumen [3,8,27,32]. The heterologous
antigens are surface expressed by fusion of the proteins to short
N-terminal part of the Nm lipoprotein fHbp [31]. Spontaneous
OMV production was triggered in batch cultures by cysteine deple-
tion of the culture media [43], which is associated with oxidative
stress responses. Additionally, high dissolved oxygen concentra-
tions were used during cultivation to enhance OMV production
[11].
This study aims to develop a production platform for Nm OMVs
expressing heterologous antigens. First a purification process for
sOMVs is designed on the available unit operations of the eOMV
purification process. Optimization of the separation of sOMVs from
the bacterial cells was required to achieve sufficient yields. Next,
the impact of expressing heterologous antigens on the growth of
the bacterial culture on the quality of OMVs expressing these
heterologous antigens is assessed. Furthermore, the characteristics
of eOMVs and sOMVs are compared.2. Methods
2.1. Bacterial strains
The H44/76 isolate of Neisseria meningitidis serogroup B [17]
was used as OMV production host. In this strain the rmpM gene
was knocked out to induce vesicle formation [41]. Furthermore,
the strain is non-encapsulated by siaD knockout, has reduced LPS
toxicity by lpxL1 knockout [44], has increased interaction with den-
dritic cells by lgtB knockout [37], and lacks the major outer mem-
brane protein and immunodominant antigen porA [40]. Outer
surface protein A (OspA) and Outer surface protein C (OspC) from
Borrelia burgdorferi were expressed in Nm as heterologous anti-
gens. The ospA and ospC genes were codon optimized for the codon
usage of Nm and expressed by placement after a hybrid porA-nadA
promotor [28]. To ensure surface exposure, OspA and OspC were
linked to fHbp (fHbp-OspA, fHbp-OspC) as based on the method
described previously [31] and placed in either rmpM or lpxL1. An
overview of the strains used in this study is given in Table 1.Table 1
Overview of bacterial strains used in this study. The heterologous antigens OspA and
OspC from B. burgdorferi were expressed in N. meningitidis.
Strain Knockout mutations Heterologous antigen
OspA OspC
Nm rmpM, siaD, lgtB, lpxL1 – –
Nm OspA rmpM, siaD, lgtB, lpxL1 in rmpM –
Nm OspC rmpM, siaD, lgtB, lpxL1 – in rmpM
Nm OspA + OspC rrmpM, siaD, lgtB, lpxL1 in lpxL1 in rmpM2.2. Batch cultivations
Pre-cultures were started by adding 10 mL of frozen working
seedlot to a shaker flask containing 155 mL chemically defined
growth medium [1]. The shaker flask was incubated in a shaker
incubator at 35 C, 200 rpm and after growth it was used to inoc-
ulate a second shaker flask. At OD590 nm = 1.5 ± 0.5 this was trans-
ferred to a bioreactor containing 3 L medium to start the batch
culture. The bioreactor (Pierre Guerin Trytoni) controlled the tem-
perature at 35 C, pH at 7.2. The dissolved oxygen tension was con-
trolled at 30% air saturation by increased agitation rate (300–
1000 rpm) followed by addition of oxygen in the overlay aeration.
The growth medium was designed such that cysteine depletion
causes growth arrest and triggers sOMV release [43]. sOMV release
can be further induced by oxidative stress from high dissolved oxy-
gen concentrations in the culture. These cultures were controlled
at 100% air saturation, further referred to as high dissolved oxygen.
Filtered off-gas (0.22 mm cut-off) was measured by a Thermo Prima
db mass spectrometer to monitor oxygen consumption and carbon
dioxide production.
2.3. Downstream processing of sOMVs
The harvested culture broth was cooled to 20 C and trans-
ferred to a tangential flow microfiltration setup (Spectrum Mini-
Kros pilot or Spectrum KR2i) with a 20 cm mPES hollow fiber
module. The hollow fiber was used according to the manufac-
turer’s instructions (Spectrum Labs). Transmembrane pressure
scouting (TMP-scouting) and flow excursion were performed
using the harvest of two 3 L batch cultures grown at 100%
DOT as described above. For the TMP-scouting, 3 L harvest was
cooled to 20 C and transferred to a tangential flow filtration
(TFF) setup using the Spectrum KR2i and Spectrum 85 cm2,
0.65 mm pore size hollow fiber module with 0.7 mm lumen
diameter. The permeate flowed back into the feed. TMP was con-
trolled by the automatic backpressure valve. For the flow excur-
sion, a similar setup was used with a new culture harvest, using
a new 85 cm2 0.65 mm pore size membrane module without
backpressure valve. The permeate flow was controlled by the
KRJ pump of the KR2i. To produce sOMVs, a 520 cm2 0.65 mm
pore size mPES hollow fiber module was used on a KroFlo Mini-
Kros Pilot TFF system (Spectrum). The cooled harvest was con-
centrated 6-fold by processing with a shear rate of 16.000 s1
and a constant flux rate of 15 L per m2 surface area per hour
(LMH). Next, the remaining sOMVs were washed out by 2 vol-
umes diafiltration by constant volume diafiltration performed
at the same operating settings, using a 10 mM Tris-HCl 3%
sucrose buffer of pH 7.2. Next, sOMVs were purified starting
with the addition of 300 U/L Benzonase (Merck) to the crude
sOMVs to digest DNA. The sOMVs were concentrated using a
790 cm2, 100 kDa cut-off mPES membrane, followed by 3 volume
diafiltration with buffer (10 mM Tris-HCl 3% sucrose buffer of pH
7.2). The concentrated OMVs were clarified by dead-end micro-
filtration (1.2 mm–0.5 mm cut off) before group separation by
size-exclusion chromatography on a Sepharose 6 Fast Flow col-
umn (GE Life Sciences). Lastly, sOMVs were sterile filtered using
a 0.2 mm cut-off dead-end filter (Pall).
2.4. Downstream processing of eOMVs
Nm eOMVs were produced based on the process described by
Van de Waterbeemd et al. [42]. In brief, the biomass of the cooled
culture harvest was concentrated 5-fold using a 790 cm2 mPES hol-
low fiber module with 0.2 mm pore size and 0.5 mm lumen diame-
ter (Spectrum Labs), followed by 2 volumes diafiltration in a buffer
suited for OMV extraction (100 mM Tris-HCl pH 8.6). eOMVs were
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Next, purification of eOMVs was identical to the purification of
sOMVs described above.2.5. Analytical methods
OMV samples were quantified by Nanoparticle Tracking Anal-
ysis (NTA) [24]. Culture samples were filtered (0.22 mm pore
size) before measurement. NTA was performed on a calibrated
NanoSight NS500 by capturing 10 captures of 30 s at 25 C. Puri-
fied water was used to prepare correct sample dilutions. Auto-
mated flow-measurements were obtained as described
previously [12]. Captures were analyzed using the NTA 3.2 soft-
ware build 3.2.16. Total protein content of purified OMV samples
was assessed using Lowry’s protein assay with Peterson’s modi-
fication and Bovine Serum Albumin as protein standard. The
assay was performed according to manufacturer’s protocol
(Sigma-Aldrich). LPS content was measured by a modified gas
chromatography method [18,45]. In brief, the LPS was quantified
based on the peak area of C14:0-3OH using C12:0-2OH as inter-
nal standard [1]. Protein composition of OMVs was assessed by
SDS-PAGE by loading OMVs with a total protein content of
4 mg on a precast polyacrylamide gel (Lonza) to perform SDS-
gel electrophoresis. The gel was stained with InstantBlue protein
stain (Expedeon).
Western blot analysis was performed as described [31] using a-
OspC Rabbit Polyclonal Antibody (Rockland) as a primary antibody
after separating the proteins on a Novex 16% Tricine Protein Gel
(ThermoFisher Scientific). As a molecular weight marker the Preci-
sion Plus Protein Standard (BioRad) was used.
For LC-MS/MS analysis, OMVs were denaturated at 100 C for
30 min in potassium phosphate buffer (100 mM, pH 7.8), also
containing 100 mM Rapigest (Waters), at a protein concentration
of 200 mg/mL. Reduction and alkylation of the proteins were per-
formed by subsequent incubations with TCEP (1 h at 55 C) and
iodoacetamide (30 min at ambient temperature in the dark). Pro-
teins were digested with LysC (0.4 mg, Roche) and trypsin (1 mg,
Promega) by overnight incubation at 37 C. Solid-phase extrac-
tion was performed to remove excess reagents using 1-mL C18
Sep-pack cartridges (Waters) according to the manufacturer’s
protocol. After drying, the peptide fraction was reconstituted in
1 mL of water containing 5% (v/v) DMSO and 0.1% (v/v) formic
acid. Nanoscale reversed-phase liquid chromatography was used
for peptide separation [25]. The peptides were measured in an
Orbitrap Fusion Lumos mass spectrometer (Thermo Scientific)
utilizing data-dependent scanning: the MS-scan (m/z 300–1500)
with an orbitrap readout (120,000 FWHM). Precursor ions with
+2 to +7 charge states (intensity threshold 25,000 counts) were
selected for collision-induced dissociation (CID) with an ion-
trap readout using default settings. Proteome Discoverer 2.1 soft-
ware (Thermo Scientific) was used for peptide identification and
quantification (based on the High-3 method). Identification of
peptides was performed against the protein database of N.
meningitidis H44/76 (NCBI 909420) and the fHbp-OspA/C con-
structs. Asparagine deamidation and methionine oxidation were
set as dynamic modifications while cysteine carbamylation was
set as static modification. The data were searched with full tryp-
sin cleavage specificity, allowing 2 missed cleavages. Precursor
ion and MS/MS tolerances were set to 5 ppm and 0.4 Da, respec-
tively. Peptides were filtered using Perculator (1% FDR). Reported
protein areas were multiplied with their respective molecular
masses and used to calculate the percentage of the protein abun-
dance for each individual protein relative to the total sum of all
identified proteins. Protein localization was predicted using
PSORTb v3.0 [47].2.6. Stability of OspA expression during cultivation
A bioreactor culture was subcultured in shaker flasks from
OD590 = 0.1 to OD590 = 3.0 ± 0.5 for over 20 generations after the
end of a batch bioreactor culture. Culture samples from the shaker
flasks as well as from the frozen seedlots, the preculture and the
bioreactor culture were analyzed for the presence of OspA by Wes-
tern blot analysis. As primary antibody a polyclonal rabbit anti-
OspA (Rockland) was used with goat-anti-rabbit IgG-AP (Southern
BioTech) as secondary antibody.3. Results
3.1. Overall process design for sOMV production
A production process for Nm sOMVs was designed based on the
scalable unit operations of the Nm detergent-free extracted OMV
(eOMV) production process (Fig. 1). The production of biomass
starts from a frozen working cell-bank, by growth in a shaker flask
(1.1). After growth, this is sub-cultured to an inoculum culture
(1.2) that is subsequently used to start a bioreactor production cul-
ture (1.3). The culture is cooled to reduce biological activity (1.4)
during OMV purification. The biomass is concentrated (2.0) for
eOMV production using tangential flow filtration (TFF). Next, the
bacteria are diafiltrated to extraction buffer on the same hollow
fiber module (2.1). eOMVs are extracted by incubation with EDTA
(2.2) and separated from the residual bacterial biomass by collect-
ing the filtrate (3.0). Next, eOMVs are purified by DNA degradation
(4.0) and concentrated on a 100 kDa cut-off hollow fiber module
(4.1). The concentrated OMVs are changed to a different buffer
(4.2) and clarified (5.1) before separation from soluble proteins
by size-exclusion chromatography (6.1). Lastly, the purified eOMVs
are filtered to obtain sterile OMVs (7.1). For sOMVs, purification
starts by separation of the sOMVs from the bacterial biomass by
tangential flow filtration (2.0). Further purification of sOMVs is
equivalent to the eOMV process, omitting the extraction process
(2.1–3.0). In the following sections the sOMV separation process
from the biomass is further discussed, followed by a proof of con-
cept of OMV production of Nm OMVs containing heterologous
antigens and analysis of their quality.3.2. Optimizing tangential flow microfiltration based recovery of OMVs
Tangential flow microfiltration was used to separate sOMVs
from the bacterial cells. A process was tested based on the process
of biomass concentration used previously in eOMV production.
Where for eOMV production tangential flow microfiltration is used
for concentrating the biomass (step 2.0), the same step is used to
remove bacterial cells in the case of sOMV production. A cooled
Nm culture was processed by operating an 0.2 mm pore size hollow
fiber filter in constant transmembrane pressure (TMP) mode. The
production of Nm sOMVs yielded a total of 4  1014 particles in
the bacteria-free OMV fraction, which corresponds to a recovery
of 77% of the 5  1014 OMVs produced in a 3 L culture (Fig. 2A).
The productivity of another culture was improved four-fold to
2.0  1015 sOMVs in 3 L culture broth by increasing the dissolved
oxygen concentration to 100% air saturation. Surprisingly, the
recovery of sOMVs in step 2.0 (TFF microfiltration) from this cul-
ture was reduced to 1.0% (Fig. 2A).
OMV induction by high dissolved oxygen concentration showed
severely reduced recovery of sOMVs using the 0.2 mm pore size
hollow fiber filter. Since the size of the OMVs (100 nm) is close
to the cutoff of the 0.2 mm pore size membrane, transmission can
be affected by small increases in OMV size or slight fouling of
the filter pores. Since we previously found that the size of OMVs
Fig. 1. Schematic production process of eOMVs and sOMVs. Production of both Nm eOMV as Nm sOMV starts by batch cultivation of N. meningitidis on chemically defined
growth medium. After bacterial growth, sOMVs can be purified from the culture supernatant directly, while the production of eOMVs requires an extraction process of the
concentrated biomass under specific conditions. Further down-stream processing of both types of OMVs consists of the same process steps: DNA removal, vesicle
concentration, buffer exchange, removal of residual proteins, and sterile filtration. The unit operations are explained in the main text.
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that the mild stress may have caused a decrease in pore size due to
DNA or other cell debris. We assessed the performance of a hollow
fiber membrane filter with increased pore size to restore the recov-
ery of sOMVs. A pore size of 0.65 mm resulted in complete retention
of bacteria, which are 0.6–1.0 mm in diameter, and OMV recovery
increased to 29% (Fig. 2B). Additionally, it was tested whether
DNA degradation by DNAse before filtration would improve the
transmission, but the transmission was similar (31%) to processing
without DNA degradation (Fig. 2B).
Further analysis of the filtration performance showed that ini-
tial transmission of OMVs over the 0.65 mm pore size membrane
was high, but reduced quickly, indicating fouling of the filter mem-
brane. To explore the possibilities of improving the recovery of
sOMVs induced by the high dissolved oxygen concentration, TMP
scouting was performed. By measuring the flux at different trans-
membrane pressures, an optimum flux can in principle be found
at increased shear rates and increased transmembrane pressures(Fig. 3A). Interestingly, we observed that the passage of OMVs
through the filter was highly reduced at increasing transmembrane
pressures (Fig. 3B), while the transmission of total protein
remained unaffected for all samples (data not shown). Especially
at a moderate shear rate of 5000 s1, the cross flow along the mem-
brane was apparently not strong enough to clean the surface. This
shear rate (5000 s1) was initially chosen due to the non-fouling
feed flow observed in the eOMV process. If only a minor amount
of fouling occurs, it reduces the possibility of the relatively large
OMVs to pass the pores of the membrane. Operating the mem-
brane at higher TMPs will thus cause a reduced recovery of OMVs.
Minimization of membrane fouling by this highly fouling cul-
ture harvest could be achieved by operating under constant perme-
ate flow instead of at constant TMP conditions. This constant flux
method ensures the lowest fouling conditions since the flow
through the pores of the membranes is limited by the permeate
pump, while the cleaning action of the flow along the membrane
is maintained. To determine the operating conditions for this
Fig. 2. N. meningitidis biomass removal and sOMV recovery by tangential flow filtration. Recovery of sOMVs by tangential flow filtration at constant TMP from a bioreactor
culture (harvest) (A). Nm sOMVs produced in a sulfur-source (cysteine) depleted culture (black) showed 77% recovery, while a sulfur-source depleted culture combined with
a high dissolved oxygen concentration (green) showed 1% recovery. Recovery of sOMVs from a culture with high oxygen concentration by tangential flow filtration at
constant TMP is optimized using an increased pore size membrane and DNAse treatment (B). (For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
Fig. 3. TMP scouting of the TFF of a dissolved oxygen induced sOMV harvest. Filter performance at varying shear rates and increasing transmembrane pressures using a N.
meningitidis high dissolved oxygen induced sOMV harvest. The resulting permeate flux in liter per m2 surface area per hour (LMH) is shown at increasing transmembrane
pressures (A). The transmission of sOMVs at increasing transmembrane pressures is given for crossflow rates at 5000 s1 shear, 10,000 s1 shear, and 16,000 s1 shear (B).
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tem can operate without accumulation of foulants) was deter-
mined at three different shear rates (Fig. 4). The shear rate of
5,000 s1 showed the lowest critical flux (10 LMH), while the shear
rates 10,000 s1 and 16,000 s1 showed higher critical fluxes
(22 LMH). Transmission of the OMVs through the membrane was
constant up to the critical flux. For the higher shear rates transmis-
sion was constant at 70%. Processing the culture harvest at high
shear rates and a flux below the critical flux should allow the pro-
cessing of the entire harvest volume with 70% transmission. By
processing 5/6th of the volume, followed by 2 volumes diafiltra-
tion, a theoretically OMV recovery of 93% could be reached.3.3. Production of meningococcal sOMVs containing heterologous
antigens
The process with optimized microfiltration (step 2.0) was used
to produce Nm sOMVs, and Nm sOMVs containing heterologousantigens. Heterologous antigens were added to sOMVs by genetical
linkage to an outer membrane linking protein of N. meningitidis to
ensure surface exposure [31]. Fusion constructs of fHbp to Outer
Surface Protein A (OspA) and Outer Surface Protein C (OspC) of Bor-
relia burgdorferi were expressed individually in Nm (Nm OspA, Nm
OspC) as well as combined (Nm OspA + OspC). The stability of the
heterologous expression of antigens was analyzed for the OspA
expressing Nm strain. Western blot analysis showed that OspA
was expressed for at least 20 generations after the end of the batch
production culture (Supplemental Fig. 1). All three strains, and the
control strain without OspA and OspC, were grown in a batch cul-
ture with cysteine depletion in combination with high dissolved
oxygen concentrations to trigger sOMV release. The growth of
the four cultures was similar during the first 7 h of cultivation
(Fig. 5). Then, a reduction in growth rate for the strains expressing
heterologous antigens was observed resulting in a shift of 4 h (Nm
OspA, Nm OspC) and 7 h (Nm OspA + C) before reaching the max-
imum carbon dioxide evolution rate. Cultures were harvested
Fig. 4. Flux excursion of the TFF of a dissolved oxygen induced OMV harvest. The performance of constant flux-mode processing of a high dissolved oxygen induced sOMV
harvest was tested. The permeate flux (grey line) at increasing transmembrane pressures (black line) was monitored at shear rates of 5000 s1 (A), 10,000 s1 (B), and
16,000 s1 (C). The resulting sOMV transmission is shown (D).
Fig. 5. Bacterial growth and sOMV production of N. meningitidis expressing B. burgdorferi antigens. Bacterial growth of Nm strains expressing heterologous antigens in batch
cultures at high oxygen concentrations is plotted (A) by the carbon dioxide evolution rate (CER). The respiratory quotient remained 1.0 ± 0.05 throughout the cultivation for
all cultures (data not shown). The resulting amounts of sOMVs in the harvested culture (harvest) and after removal of bacterial cells (crude sOMV) are shown in panel B.
M.J.H. Gerritzen et al. / Vaccine 37 (2019) 6978–6986 6983
6984 M.J.H. Gerritzen et al. / Vaccine 37 (2019) 6978–69866 ± 1 h after reaching the maximum carbon dioxide evolution rate,
resulting in an average harvest of 2.0  1015 sOMVs in 3 L culture.
The optimized microfiltration process results in an average recov-
ery of 90 ± 17% of sOMVs. Next, the sOMVs were further purified
using the same unit operations as the detergent-free purification
process (data not shown). In brief, sOMVs were treated with
DNAse, concentrated and diafiltrated. After clarification, the
sOMVs were further purified using size-exclusion chromatography
and filter sterilized.
3.4. sOMV characteristics
The optimized sOMV production process was used to produce
sOMVs and the effect of introducing different antigens on the char-
acteristics of sOMVs was assessed. Purified sOMVs were highly
similar in size distribution with a mean particle size of 105 nm
(Fig. 6A). The average composition of purified OMVs also showed
high similarities for the sOMVs containing heterologous antigens.
The ratio of protein per vesicle and the ratio of LPS per vesicle
was determined by combining concentration measurements of
protein and LPS to the concentration of particles (Fig. 6B). The pro-
tein pattern on an SDS-PAGE gel is also very similar (Fig. 6C). The
most abundant protein in all sOMVs is PorB (33.8 kDa). A minor
amount of OspA (29.1 kDa) can be observed in the Nm OspA and
Nm OspA + OspC OMVs. The fusion construct of OspC to fHbp
(10.8 kDa) was not observed by SDS-PAGE, however it is visible
by Western blot (Fig. 6D) at the expected size in the Nm OspC
sOMVs and the Nm OspA & OspC sOMVs. Based on LC-MS/MS, an
estimated relative protein content of 0.04% (w/w) and 0.07% (w/
w) OspC was retrieved for the Nm OspC and Nm OspA + OspC
OMVs. The estimated relative content of OspA in Nm OspA and
Nm OspA + OspC OMVs was 2.2% (w/w) and 0.31% (w/w). SinceFig. 6. Characteristics of the OMVs. Nm sOMVs produced at high oxygen concentrations u
Nm sOMVs containing heterologous antigens shows a mode size of 105 nm (A). The com
OMV and amount of LPS per protein (B). Protein composition of the sOMVs is analyzed
different production methods (eOMV, sOMV by cysteine depletion (sOMV 30), sOMV by h
location was assessed by PSORTb (E).repetitive epitope presentation is required in proper vaccine func-
tion [16], we estimated the average number of OspA and OspC
antigens per vesicle based on the particle and protein concentra-
tion and the relative abundance of the antigens. The strains
expressing single antigens contain 55 and 2 molecules of OspA
and OspC per OMV, respectively. Simultaneous expression yields
10 molecules of OspA and 4 molecules of OspC per OMV.
Besides OspA and OspC, the overall protein composition of
OMVs produced by the different production methods (eOMV,
sOMV and sOMV by increased oxygen concentration) were com-
pared. Based on the LC-MS/MS data the subcellular protein location
of the OMV proteome was predicted by PSORTb. The sOMVs pro-
duced at high dissolved oxygen concentrations using the improved
purification process are mainly composed of outer membrane pro-
teins (55%) and cytoplasmic proteins (25%). The sOMVs produced
at standard oxygen concentration show a comparable composition
(Fig. 6E). However, eOMVs contain more cytoplasmic proteins
(39%) than outer membrane proteins (37%) and are also enriched
in cytoplasmic membrane associated proteins. Overall, eOMVs
show a different protein composition to sOMVs. Expressing OspA
or OspC on the surface of sOMVs does not impair the tested char-
acteristics of the sOMVs. Furthermore, the results show that
sOMVs formed at high dissolved oxygen concentrations have sim-
ilar protein compositions to sOMVs produced at standard oxygen
concentration.
4. Discussion
In this study, Nm sOMVs containing B. burgdorferi antigens were
produced in a batch process by a purification process with scalable
unit-operations. The heterologous antigens were expressed on the
outer surface of the bacterium and were found in spontaneouslysing the improved purification method were characterized. The size distribution of
position of the sOMVs is shown in amount of protein per OMV, amount of LPS per
by SDS-PAGE (C). OspC is visualized by Western blot (D). Proteins from OMVs with
igh dissolved oxygen (sOMV 100) were measured by LC-MS/MS and their subcellular
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geous over eOMVs, because no OMV-extraction step is required,
resulting in fewer unit operations. Here we applied high dissolved
oxygen concentrations to bacterial cultures to stimulate sOMV pro-
duction. Applying high dissolved oxygen concentrations to trigger
sOMV release resulted in increased productivity, but was lowering
the recovery during microfiltration. Microfiltration optimization
showed that at constant TMP, sOMV transmission, but not protein
transmission, is reduced in slightly fouling conditions. Using a lar-
ger pore size membrane and operating the tangential flow filtra-
tion at a constant permeate flux of 50% of the critical flux,
improved the recovery to 90%. sOMV quality attributes were highly
consistent between the different antigen expressing strains, and
highly comparable to sOMVs produced at standard oxygen concen-
trations. However, the Zeta potential was measured in one of the
intermate samples and a lower potential was found in the OMVs
purified from the cultivations with a high dissolved oxygen con-
centration as compared to a low dissolved oxygen concentration.
This reduced potential could have aided to the initial fouling of
the membrane before optimization.
The amount of Nm sOMVs recovered in this study reached
2 * 1015 OMVs for a 3 L culture, corresponding to approximately
90 mg of OMV associated protein per liter culture (mg/L). This is
an improvement over N. meningitidis eOMV production, where 20
to 50 mg/L was reached [42], and N. meningitidis dOMV production
where up to 22 mg/L was reached [4,9]. It should be noted that the
strains used in the other studies harbored different mutations than
this strain. The parental strain, however, is the same. Other sOMV
production described in literature include the Shigella sonnei sOMV
yields of 140 mg/L [33], and 68 to 80 mg/L [10]. These yields were
obtained from high-cell density cultures (OD600 35 to OD600 45),
while this study is based on cultivation of up to 4 g dry weight
per liter culture (gdw/L). Interestingly a high cell density N. menin-
gitidis perfusion cultivation has been described to reach a biomass
concentration of 58 gdw/L [6], indicating that there is a possibility
of process intensification if enhanced productivities are desired.
Expressing heterologous antigens in N. meningitidis resulted in
cultures with a lowered growth rate, however, production of
sOMVs was maintained. More research is needed to assess the
repeatability, the effect of additional antigens, and possibly the
screening of clones or the use of an inducible production system
could further improve the productivity of the heterologous
antigens.
The number of antigens present on OMVs reported here are
between 2 and 55 antigenic proteins per vesicle. These values were
based on semi-quantitative LC-MS/MS protein composition mea-
surements combined with nanoparticle tracking analysis of the
OMV concentration and should thus be interpreted with some cau-
tion. Furthermore, the level of expression could have been influ-
enced by the genomic location of the heterologous antigen as
OspA was expressed by insertion in either rmpM or lpxL1. Hypo-
thetically more antigens per vesicle would increase the potency
of the composition, but it is unknown what an optimum composi-
tion would be. Together, these design criteria are important
aspects of future research.
In designing an OMV production process, sOMVs are advanta-
geous over eOMVs from a process perspective. Here we show that
the composition of eOMV differs from sOMV, but it is unknown
what the effect of OMV type is on the immunogenicity. sOMVs
are enriched in outer membrane proteins, which are usually
immunogenic proteins. For a nonavalent PorA based Nm serogroup
B vaccine, the cross-protection against PorA not included in the
strain were assessed for dOMV, eOMV and sOMV [41]. dOMVs
did not show bactericidal titers against strains not included in
the vaccine, whereas eOMVs showed some cross-protection
against strains expressing PorA not included in the vaccine. sOMVsdid elicit broad cross protection against all tested strains and a
minor response against a strain lacking PorA. sOMVs are thus
advantageous over eOMV and dOMV for vaccine compositions pro-
viding protection against the OMV-producing strain. However, fur-
ther research is required to elucidate the differences between the
type of OMV on the efficacy of an OMV-based vaccine platform.
In this platform design we use a pathogenic bacterium as pro-
duction host, in contrast to common production bacteria that are
closely related to commensal bacteria. This approach ensures that
the vaccine platform does not cause unwanted responses against
commensal bacteria. Another concern of vaccine platforms is the
possible response against the platform itself, possibly causing
immune dominance of the carrier. Currently it is unknown if
reduction of the antigenicity of the OMV-backbone is required to
yield an effective vaccine platform. Here we aimed to reduce the
antigenic content of the backbone by removing the capsular
polysaccharide, LPS and the antigen outer membrane porin A
(PorA). However, the OMVs showed to be enriched in another
porin, PorB. Nm PorB is a TLR-2 ligand [36], that may be advanta-
geous because of its adjuvating function [30]. The observation of a
large amount of PorB in sOMVs is contrary to the proteome of Nm
sOMVs described by Lappann et al., where sOMVs were found to be
reduced in PorA and PorB [21], which bind to the periplasmic pro-
tein RmpM [23]. Here we used a Nm strain without RmpM to
enhance OMV release, which could explain the increase of PorB,
since linkage of PorB with RmpM and the peptidoglycan is not pos-
sible in this strain.
Overall, this study demonstrates the feasibility of the produc-
tion of an OMV-based vaccine platform based on the expression
of heterologous antigens on N. meningitidis sOMV. We showed that
the addition of two Lyme disease antigens affected the growth, but
yielded similar amounts of OMVs with similar characteristics as
the Nm OMV control. Purification of sOMVs was possible by opti-
mizing the purification process. By applying high oxygen concen-
trations to the bacteria, yields of 90 mg/L highly pure OMVs were
obtained. With this process it becomes feasible to produce suffi-
cient N. meningitidis OMVs with various heterologous antigens
and study their potential as future vaccines.
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